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Abstract
Background: The aim of our study was to examine whether increased circulating total cell-free
DNA levels are related to the clinical characteristics and standard laboratory parameters of
preeclamptic patients, to markers of inflammation, endothelial activation or injury, oxidative stress
and to cell-free fetal DNA levels.
Methods: Circulating total cell-free DNA was measured by real-time quantitative PCR in plasma
samples obtained from 67 preeclamptic and 70 normotensive pregnant women. Standard
laboratory parameters, C-reactive protein, plasma von Willebrand factor antigen, plasma
fibronectin, plasma malondialdehyde and cell-free fetal DNA levels were also determined.
Results and Conclusion: Circulating total cell-free and fetal deoxyribonucleic acid levels were
significantly elevated in pregnancies complicated by preeclampsia (median: 11.395 vs. 32.460 and
0.001 vs. 0.086 pg/μl; P < .001). The quantity of plasma total cell-free DNA did not correlate with
most of the laboratory parameters, except for serum aspartate aminotransferase and alanine
aminotransferase activities (correlation coefficient: 0.31; P = 0.012 and 0.46; P < .001). There was
no correlation with clinical characteristics, including body mass index. The releases of both free
fetal and total cell-free deoxyribonucleic acid were found to be affected in preeclampsia.
Hepatocellular necrosis seems to be responsible - at least partly - for increased circulating total
DNA levels in preeclampsia, as suggested by the significant correlation with liver enzyme activities.
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Background
Preeclampsia is one of the leading causes of maternal
and perinatal morbidity and mortality in the developed
world [1,2]. It is characterized by hypertension and
proteinuria developing after midgestation in previously
normotensive pregnant women. Although the exact
etiology of preeclampsia remains elusive [2], there
appears to be a defect in trophoblast invasion with
diminished infiltration and modification of the spiral
arteries leading to impaired placentation and subsequent
uteroplacental insufficiency [3]. The ischemic and
oxidatively stressed placenta releases proinflammatory
(Th1) cytokines, lipid peroxidation products and tro-
phoblast debris (syntitiotrophoblast microfragments,
cytokeratin, soluble DNA and RNA of fetal origin and
even trophoblast cells) into the maternal circulation,
which in turn trigger an excessive maternal systemic
inflammatory response [4-6]. The systemic inflammatory
response with systemic oxidative stress and generalized
endothelial dysfunction appears to be the cause of the
maternal syndrome of preeclampsia [6]. Several mater-
nal and familiar factors such as maternal age and body
mass index, chronic hypertension or renal diseases, and
hypertension in family history have been described as
risk factors of preeclampsia. In the last ten years, several
studies have reported the increased level of fetal cells,
cell-free maternal and fetal DNA in the maternal
circulation [7]. While the latter seems to reflect placental
injury, the reason for increased cell-free maternal DNA
levels in preeclampsia is currently unknown [8,9]. The
aim of our study was to measure and compare the
concentration of cell-free (cf) and cell-free fetal (cff)
DNA levels in the plasma of preeclamptic and normo-
tensive pregnant women, and to determine whether
increased circulating cf DNA levels are related to clinical
characteristics and standard laboratory parameters of
preeclamptic patients, to markers of inflammation (C-
reactive protein), endothelial activation (von Willebrand
factor antigen) or endothelial injury (fibronectin),
oxidative stress (malondialdehyde) and to cell-free fetal
DNA levels.
Methods
Patients
This study was performed in a retrospective manner.
Sixty-seven plasma samples were collected from women
with preeclampsia during pregnancy; these samples were
stored frozen. Preeclampsia was determined by a blood
pressure of ≥ 140/90 mmHg and an associated protei-
nuria of ≥ 300 mg/24 h after 20 weeks’ gestation. Seventy
samples were taken from normotensive women with
normal pregnancies. All women were pregnant with a
single fetus; 36 of those with preeclampsia had a single
male fetus, as did 25 of the control cohort. Pregnant
women with eclampsia or HELLP syndrome (hemolysis,
elevated liver enzymes, and low platelet count) were not
enrolled in this study. The study protocol was approved
by the Regional Institutional Committee of Medical
Ethics at the Semmelweis University, and written
informed consent was obtained from each patient. The
study was conducted in accordance with the Declaration
of Helsinki.
DNA extraction and PCR analysis
Blood was collected into sterile EDTA tubes, and plasma
was rapidly separated by centrifugation at 3000 g and
stored frozen at -80°C until the analyses were per-
formed. DNA was extracted from 400 μL plasma with the
High Pure PCR Template Preparation Kit (Roche
Diagnostics, Mannheim, Germany) according to the
manufacturer’s protocol. Strict anticontamination proce-
dures were used throughout. These included the use of
aerosol-resistant tips throughout all the experimental
procedures and the addition of multiple negative control
samples in each analysis. The DNA was eluted in 50 μL
of elution buffer solution, of which 2 μL was used as a
template for the PCR reaction.
SYBR Green PCR analysis
For the SYBR Green real-time PCR analysis, we used a
LightCycler 1.0 System (Roche Diagnostics, Mannheim,
Germany). Circulating male fetal DNA was detected with
the following primers for the SRY gene located on the Y
chromosome: forward, SRY F, 5’-ggc aac gtc cag gat aga
gtg a-3’, reverse 5’-tgc tga tct ctg agt ttc gca tt-3’. To
determine the total amount of circulating DNA present
in the maternal plasma samples, we used a SYBR Green
assay and primers for the globin gene, which is present in
all genomes. In this analysis, the following primers were
used: forward 5’-aca caa ctg tgt tca cta gc-3’, reverse 5’-caa
ctt cat cca cgt tca cc-3’. The PCR analysis was carried
out in 10-μL reaction volumes containing 1 μl DNA,
2,5 pmol/L of each amplification primer, 2 μl of DNA
Master SYBR Green I mix (LightCycler FastStart DNA
Master SYBR Green I kit: Taq polymerase, dNTP, MgCl2),
and 6 μl of nuclease free water.
The analysis was designed in such a manner that
identical thermal profiles could be used for both the
SRY and globin SYBR Green assays, because this allowed
us to analyze both of these markers on the same plate in
the same analytic run. The PCR was carried out in 40
cycles under the following conditions: initial denatura-
tion 8 min on 95°C, 5 sec denaturation on 95°C, 10 sec
annealing on 60°C, 15 sec extension on 72°C, cooling to
4°C till capillar removement. To determine the number
of copies of circulating DNA present in the plasma
sample, a standard dilution curve with a known
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concentration of male genomic DNA was used. All
samples were analyzed in duplicate and scored in a
blinded manner.
Laboratory parameters
Standard laboratory parameters (clinical chemistry) and
C-reactive protein (CRP) levels were determined by an
autoanalyzer (Cobas Integra 800, Roche, Mannheim,
Germany) using the manufacturer’s kits. Plasma von
Willebrand factor antigen (VWF:Ag) levels were quanti-
fied by ELISA (Dakopatts, Glostrup, Denmark), while
plasma fibronectin concentration by nephelometry
(Dade Behring, Marburg, Germany), according to the
manufacturer’s instructions. Plasma malondialdehyde
levels were measured by the thiobarbituric acid-based
colorimetric assay [10].
Data analysis
The normality of continuous variables was assessed using
the Shapiro-Wilk’s W-test. As the continuous variables
were not normally distributed, nonparametric statistical
methods were used. To compare continuous variables
between the two groups, the Mann-Whitney U-test was
applied, while to compare categorical variables between
the groups, the Fisher exact and Pearson c2 tests were
performed. As plasma total and fetal DNA levels showed
skewed distributions, we performed analyses of covar-
iance (ANCOVA) with logarithmically transformed data.
The Spearman rank order correlation was used to
calculate correlation coefficients. Statistical analyses
were carried out using the following software: STATISTICA
(version 7.1; StatSoft, Inc., Tulsa, Oklahoma, USA) and
Statistical Package for the Social Sciences (version 15.0 for
Windows; SPSS, Inc., Chicago, Illinois, USA). For all
statistical analyses, p < 0.05 was considered statistically
significant.
Results
In this study, performed retrospectively and in a blinded
manner, 67 plasma samples were obtained from
pregnant women with preeclampsia. Thirty-six of them
carried male fetuses (gestational age at blood draw,
median (range): 37.5 (30-41)). Seventy plasma samples
were obtained as control from normotensive pregnant
women, 25 of whom carried male fetuses (gestational
age at blood draw, median (range): 36 (29-39)).
The clinical characteristics of the studied pregnant
women are shown in Table 1. The measured laboratory
parameters were significantly different between the two
groups, except for serum AST activities (Table 2).
Quantifying the amount of Y chromosome-specific
DNA, we were able to confirm that the levels of male
fetal DNA were significantly elevated in pregnancies
complicated by preeclampsia compared to the normo-
tensive control subjects (median: 0.086 pg/μl vs. 0.001
pg/μl plasma; P < .001; Figure 1). Data regarding the
quantity of total cell-free DNA (globin) also confirmed
significant difference between the two groups (median:
32.460 pg/μl vs. 11.395 pg/μl plasma; P < .001; Figure 2).
As BMI and gestational age at blood sampling, which are
known to affect plasma DNA levels, differed significantly
between the preeclamptic and the control group,
adjusted values were calculated with analyses of covar-
iance (ANCOVA). The differences in fetal and total cell-
free DNA levels between the two study groups remained
Table 1: Clinical characteristics of normotensive, healthy pregnant women and preeclamptic patients
Variable Controls (n = 70) Preeclampsia (n = 67) Statistical significance (p value)
Age (years) 30 (17-44) 29 (19-42) NS
BMI at blood draw (kg/m2) 25.9 (19.0-42.0) 30.0 (20.6-38.3) <0.001
Smokers 0 (0%) 3 (4.5%) NS
Primiparas 45 (64.3%) 43 (64.2%) NS
Systolic blood pressure (mmHg) 110 (80-138) 160 (135-220) <0.001
Diastolic blood pressure (mmHg) 70 (55-86) 100 (90-131) <0.001
Gestational age at blood draw (weeks) 35 (20-40) 38 (30-41) <0.001
Gestational age at delivery (weeks) 39 (35-41) 38 (33-41) <0.05
Fetal birth weight (grams) 3500 (2650-4400) 3200 (1400-4200) <0.001
Fetal growth restriction 0 (0%) 11 (16.4%) <0.001
Data are presented as median (range) for continuous variables and as number (percent) for categorical variables.
NS: not significant; BMI: body mass index.
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Table 2: Laboratory parameters of normotensive, healthy pregnant women and preeclamptic patients
Variable Controls (n = 70) Preeclampsia (n = 67) Statistical significance (p value)
Serum BUN level (mmol/l) 2.7 (1.7-4.8) 3.4 (0.8-6.5) <0.001
Serum creatinine level (μmol/l) 47 (34-79) 63 (36-95) <0.001
Serum bilirubin level (μmol/l) 5.1 (1.8-15.2) 7.4 (2.1-20.9) <0.001
Serum AST activity (U/l) 19 (10-38) 19 (10-148) NS
Serum ALT activity (U/l) 12 (7-32) 15 (6-233) <0.05
Serum LDH activity (U/l) 159 (93-211) 192 (113-403) <0.001
Serum CRP level (mg/l) 3.6 (0.5-28.0) 6.7 (0.3-36.9) <0.05
Plasma VWF:Ag level (%) 129.3 (47.8-297.1) 187.1 (43.3-423.0) <0.001
Plasma fibronectin level (g/l) 0.33 (0.14-0.84) 0.58 (0.02-2.13) <0.001
Plasma malondialdehyde level (nmol/ml) 14.74 (6.19-36.52) 18.62 (10.75-24.65) <0.001
Plasma total DNA level (pg/μl) 11.395 (0.425-256.3) 32.460 (1.670-602.7) <0.001
Log (total DNA level) (pg/μl) (adjusted mean ± SE) 1.145 ± 0.066 1.513 ± 0.086 <0.05
Plasma fetal DNA level (pg/μl) 0.001 (0.0-0.845)† 0.086 (0.002-3.200)‡ <0.001
Log (fetal DNA level) (pg/μl) (adjusted mean ± SE) -2.705 ± 0.310† -0.994 ± 0.326‡ <0.05
Data are presented as median (range) for continuous variables.
NS: not significant; SE: standard error; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate
dehydrogenase; CRP: C-reactive protein; VWF:Ag: von Willebrand factor antigen; DNA: deoxyribonucleic acid.
† n = 25.
‡ n = 36.
Figure 1
Plasma fetal deoxyribonucleic acid (DNA) levels in
normotensive, healthy pregnant women and
preeclamptic patients. Middle point: median, whisker:
25-75 percentile.
Figure 2
Plasma total deoxyribonucleic acid (DNA) levels in
normotensive, healthy pregnant women and
preeclamptic patients. Middle point: median, whisker:
25-75 percentile.
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significant even after adjustment for maternal age, BMI
and gestational age at blood draw in ANCOVA (Table 2).
Correlation coefficients with p values between clinical
characteristics and laboratory parameters of preeclamptic
patients and plasma total DNA levels are presented in
Table 3. Total cell-free DNA levels showed no significant
correlations with the clinical characteristics of pree-
clamptic patients, including BMI. Furthermore, the
quantity of total plasma free DNA did not correlate
with most of the laboratory parameters including plasma
cff DNA levels, except for serum aspartate aminotrans-
ferase and alanine aminotransferase activities (correla-
tion coefficient: 0.31; P = 0.012 and 0.46; P < .001).
The sample size of the preeclamptic group allowed us to
detect a correlation coefficient (rho) of 0.30 or higher, at
a Type I error rate of 0.05, with a statistical power of at
least 80%.
Comment
Several papers described previously that fetal-maternal
cell trafficking was significantly disturbed in pregnancies
complicated by preeclampsia, with elevated numbers of
fetal cells detected in the maternal circulation during
these pregnancies [11-13]. Lo et al. [14] showed that the
fetal circulating DNA level was elevated in a similar
manner during pregnancies complicated by preeclamp-
sia [5]. We were able to confirm the latter observation in
this study by showing that the levels of circulating total
and fetal DNA were significantly elevated in women with
preeclampsia compared to the control group. Our study
also confirmed that the quantification of fetal and total
circulating DNA by real-time PCR was both reliable and
reproducible. In addition to previous findings, with
collected data regarding clinical characteristics and
measuring different laboratory parameters specific to
renal and liver function, inflammation, endothelial
activation/damage and oxidative stress, we were able to
analyze the correlation between the quantity of cell-free
DNA and these parameters first in the literature.
Although the exact mechanism leading to the release of
free extracellular DNA into the circulation is not yet clear
[15], currently the most favored explanation for the
release of DNA fragments is through apoptosis or some
other form of cell death [16-18]. Some other studies,
however, have indicated that a normal physiological
process may be involved in the release of free circulating
DNA [15]. In contrast to Zhong et al. [8], we did not find
a correlation between cf DNA and cff DNA levels, which
indicates that the amount of circulating total and fetal
DNA does not increase similarly in preeclampsia.
Indeed, the median plasma level of total DNA was
2.85 times higher in our preeclamptic group, while that
of fetal DNA elevated 86-fold in preeclampsia. The latter
seems to reflect extensive placental injury in the disease.
The clinical characteristics of our preeclamptic patients,
including body mass index, did not affect plasma total
DNA concentrations, which is at variance with previous
observations. Our data did not confirm any correlation
between the markers of endothelial cell activation/
damage and the level of total cell-free DNA, which
suggests that the elevation of the DNA amount is caused
by another mechanism and the previously suggested
endothelial dysfunction is not the primary cause that
leads to the increased plasma DNA level observed in
preeclampsia. Inflammatory cytokines and reactive oxy-
gen species might damage cellular membranes and DNA
Table 3: Correlation coefficients with p values between clinical
characteristics and laboratory parameters of preeclamptic
patients and plasma total DNA levels
Variable Correlation
coefficient
Statistical
significance
(p value)
Age -0.04 0.72
BMI at blood draw 0.18 0.23
Systolic blood pressure -0.10 0.43
Diastolic blood pressure -0.21 0.087
Gestational age at blood draw 0.10 0.40
Gestational age at delivery 0.02 0.87
Fetal birth weight -0.01 0.96
Serum BUN level -0.07 0.57
Serum creatinine level 0.03 0.83
Serum bilirubin level 0.06 0.62
Serum AST activity 0.31 0.012
Serum ALT activity 0.46 <0.001
Serum LDH activity 0.17 0.23
Serum CRP level 0.04 0.76
Plasma VWF:Ag level -0.18 0.14
Plasma fibronectin level 0.01 0.96
Plasma malondialdehyde level -0.11 0.36
Plasma fetal DNA level‡ 0.14 0.41
BMI: body mass index; BUN: blood urea nitrogen; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehy-
drogenase; CRP: C-reactive protein; VWF:Ag: von Willebrand factor
antigen; DNA: deoxyribonucleic acid.
‡ n = 36.
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in preeclampsia. Nevertheless, total cell-free DNA levels
were not related to markers of inflammation and
oxidative stress in our preeclamptic group. Instead,
only liver enzyme activities showed significant correla-
tions with plasma total DNA levels, which suggests that
hepatocellular necrosis might account - at least in part -
for increased circulating total DNA levels in preeclamp-
sia. Interestingly, plasma total DNA levels were found
previously to be significantly higher in HELLP syndrome
than in preeclampsia without HELLP syndrome [19].
HELLP syndrome is characterized by extensive tissue
damage (hepatocellular necrosis and hemolysis), which
supports the hypothesis that cellular necrosis might be
responsible for increased cell-free DNA levels in the
maternal circulation, at least in preeclampsia. However,
it is also possible that another unrelated mechanism,
such as release from activated granulocytes and other
white blood cells, accounts primarily for the increase in
circulating DNA levels associated with preeclampsia. The
lack of correlation between increased circulating total
DNA levels and several measured laboratory markers in
preeclampsia could not completely exclude the relation-
ship of cell-free DNAwith the corresponding pathological
processes. The release rate, clearance rate and half-lives of
the investigated markers may be different from those of
cell-free DNA, which might also explain the lack of
correlation. More detailed studies will be necessary to
elucidate the underlying mechanisms and biochemical
background of this medically relevant disorder. Our
results provide some new data for further investigations.
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